ADMA Advances SG-001 to cGMP Production, Eyes $300–$500M Peak Revenue
ADMA sits 38% above its 52-week low of $7.21.
Summary
ADMA is moving its SG-001 candidate into cGMP lot production in H2 2026, with a pre-IND submission to the FDA planned by year-end. Management estimates $300–$500M in annual revenue if approved, a significant potential addition to the current $530–$560M 2026 revenue guide. The pipeline update comes alongside a reaffirmed full-year outlook and follows a strong Q2 where ASCENIV sales grew 24%. The securities fraud lawsuit remains an overhang, but the SG-001 progress adds a new growth narrative.
At the time of this announcement, ADMA was trading at $9.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $7.21 to $20.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.